🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are increasing around the world, with figures suggesting more than 82 million new cases each year. Notably increased rates are observed in the African continent and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the face of growing infection rates, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Gain Clearance

Zoliflodacin, also known as a brand name, was cleared by the American regulatory agency in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists believe that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.

“This milestone signifies a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

Based on findings released by a prominent scientific publication, the new drug eradicated more than 90% of uncomplicated infections. This places it at an comparable level with the current standard treatment, which uses two antibiotics. The trial included over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to make available and distribute the drug in a wide range of developing nations.

Doctors treating patients have voiced optimism. Access to a one-pill regimen of this kind is seen as a "game-changer" for managing the epidemic. This is viewed as essential to lessen the impact of the illness for people and to halt the transmission of extremely resistant gonorrhoea around the world.